Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis Inc (NQ: PSNL )

1.275 +0.065 (+5.37%)
Streaming Delayed Price Updated: 12:05 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Personalis Inc

< Previous 1 2 3 4 Next >
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Personalis, Inc.
Via Business Wire
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
From Personalis, Inc.
Via Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
From Personalis, Inc.
Via Business Wire
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
From Personalis, Inc.
Via Business Wire
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
From Personalis, Inc.
Via Business Wire
Personalis Reports Third Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
From Personalis, Inc.
Via Business Wire
Personalis to Announce Third Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
From Personalis, Inc.
Via Business Wire
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
From Personalis, Inc.
Via Business Wire
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
From Personalis, Inc.
Via Business Wire
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis Reports Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Personalis to Announce Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Dr. Kenneth J. Widder Joins Personalis Board of Directors
From Personalis, Inc.
Via Business Wire
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
From Personalis, Inc.
Via Business Wire
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
From Personalis, Inc.
Via Business Wire
Personalis Reports First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.